Edition:
United Kingdom

People: Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

17.22USD
16 Jul 2019
Change (% chg)

-- (--)
Prev Close
$17.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
51,487
52-wk High
$34.65
52-wk Low
$8.01

Palleiko, Benjamin 

Mr. Benjamin L. Palleiko is Chief Financial Officer, Chief Business Officer of KalVista Pharmaceuticals, Inc. Mr. Palleiko was hired as Chief Financial Officer of KalVista Limited in August 2016 and was appointed as our Chief Financial Officer in November 2016 in connection with the reverse acquisition transaction. Prior to joining us, Mr. Palleiko was a Managing Director of H.C. Wainwright & Co. LLC since January 2015. Mr. Palleiko also co-founded a private oncology drug development company, Cielo Therapeutics, Inc., in July 2012. Mr. Palleiko served as Chief Financial Officer of Nostrum Pharmaceuticals LLC, a specialty generic pharmaceuticals company, from January 2012 to December 2013. He previously was Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings Inc. and Penwest Pharmaceuticals Co. Earlier in his career Mr. Palleiko was an investment banker with the firms Robertson Stephens and SunTrust Robinson Humphrey. Mr. Palleiko holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and M.A. in International Relations from the University of Chicago. He served as a Naval Aviator in the U.S. Navy.

Basic Compensation

Total Annual Compensation, USD 647,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 173,831
Fiscal Year Total, USD 820,831

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --